Bone health in children undergoing solid organ transplantation

Area of Science:

• Pediatric Endocrinology
• Transplantation Medicine
• Metabolic Bone Disease

Background:

• Pediatric solid organ transplant recipients are susceptible to metabolic bone disease pre- and post-transplant.
• Childhood fractures increase adult fracture risk, necessitating vigilant monitoring in transplant patients.
• Emerging research implicates fibroblast growth factor 23 in CKD-MBD and hepatic osteodystrophy.

Approach:

• Dual X-ray absorptiometry (DXA) is standard for bone mass assessment in children.
• Quantitative computer tomography (QCT) is an emerging tool, particularly for glucocorticoid-induced osteoporosis.
• Monitoring bone mineral density before and after transplantation is essential.

Key Points:

• Bone mineral density can decrease within 3-6 months post-transplantation, influenced by immunosuppressants like glucocorticoids.
• Fibroblast growth factor 23 plays a role in metabolic bone disease pathogenesis in CKD-MBD and hepatic osteodystrophy.
• QCT is a promising imaging modality for pediatric patients with glucocorticoid-induced osteoporosis.

Conclusions:

• Optimizing mineral homeostasis, nutrition, and physical conditioning post-transplant is vital.
• Early detection and management of metabolic bone disease enhance long-term bone health in pediatric transplant survivors.
• Addressing metabolic bone disease improves the transition of pediatric transplant recipients into adulthood.